Presentation Information
[L2-03]Vaccine development with Rhabdovirus negative Sf-RVN cell line
*Sadao Ozawa1 (1. Merck Ltd)
The Baculovirus Expression Vector System (BEVS) using the Sf-9 cell line has been used for protein expression since the 1980s due to its ease of handling transient expression and scalability. It is also used to produce vaccines such as FluBlok and AAV gene therapy vectors. More recently, BIICs (Baculovirus Infected Insect Cells) have also been used to reduce the cost of baculovirus stock for manufacturing.
A 2014 report by the FDA Retrovirus Laboratory of an unknown rhabdovirus contamination in the Sf-9 cell line prompted calls for rhabdovirus clearance in bioprocesses. Until then, Sf-9 and BEVS had been used in the development of numerous vaccines and AAVs, but the majority of projects were put on hold or halted.
In 2019, Merck obtained a license to manufacture pharmaceuticals using a rhabdovirus-negative strain screened from Sf-9, which ensures safety against rhabdoviruses. We started tp providing it for vaccine development as the Sf-RVN strain in 2022. Furthermore, we offer EX-CELL CD Insect Medium, a CD medium optimized for cell growth and BEVS expression, as a platform medium for Sf-RVN.
In this presentation, we will introduce the features that support the safety and regulatory compliance of Sf-RVN and its performance.
A 2014 report by the FDA Retrovirus Laboratory of an unknown rhabdovirus contamination in the Sf-9 cell line prompted calls for rhabdovirus clearance in bioprocesses. Until then, Sf-9 and BEVS had been used in the development of numerous vaccines and AAVs, but the majority of projects were put on hold or halted.
In 2019, Merck obtained a license to manufacture pharmaceuticals using a rhabdovirus-negative strain screened from Sf-9, which ensures safety against rhabdoviruses. We started tp providing it for vaccine development as the Sf-RVN strain in 2022. Furthermore, we offer EX-CELL CD Insect Medium, a CD medium optimized for cell growth and BEVS expression, as a platform medium for Sf-RVN.
In this presentation, we will introduce the features that support the safety and regulatory compliance of Sf-RVN and its performance.
Comment
To browse or post comments, you must log in.Log in